
|Articles|October 1, 2012
Various factors dictate which neuromodulator to use, and when
As research and clinical experience continue to underscore differences between the three neuromodulators available in the United States, picking a product for a given clinical situation rests largely upon individual preference, according to Joel L. Cohen, M.D., who spoke earlier this year at MauiDerm 2012: Advances in Cosmetic and Medical Dermatology.
Advertisement
Newsletter
Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Dermatology Times
1
Clascoterone 5% Delivers Strong Phase 3 Hair-Growth Results
2
Top 5 Articles of the Week: November 30-December 5
3
The Weekly Roundup: December 1-5
4
ICYMI: First Patient Dosed in Global Phase 2 Study of Oral TYK2 Inhibitor Soficitinib for PN
5



















